CN103263674A - Tumor targeting material with tumor penetrating property, preparation method and applications thereof - Google Patents
Tumor targeting material with tumor penetrating property, preparation method and applications thereof Download PDFInfo
- Publication number
- CN103263674A CN103263674A CN201310166384XA CN201310166384A CN103263674A CN 103263674 A CN103263674 A CN 103263674A CN 201310166384X A CN201310166384X A CN 201310166384XA CN 201310166384 A CN201310166384 A CN 201310166384A CN 103263674 A CN103263674 A CN 103263674A
- Authority
- CN
- China
- Prior art keywords
- tumor
- polyethylene glycol
- penetration performance
- tumor penetration
- phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 61
- 239000000463 material Substances 0.000 title claims abstract description 34
- 230000008685 targeting Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000000149 penetrating effect Effects 0.000 title abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 29
- 229920001184 polypeptide Polymers 0.000 claims abstract description 28
- 239000002502 liposome Substances 0.000 claims abstract description 21
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 239000000693 micelle Substances 0.000 claims abstract description 6
- 229920001400 block copolymer Polymers 0.000 claims abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 102
- -1 palmityl PHOSPHATIDYL ETHANOLAMINE Chemical class 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 230000035515 penetration Effects 0.000 claims description 20
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 150000001413 amino acids Chemical group 0.000 claims description 9
- 239000004698 Polyethylene Substances 0.000 claims description 7
- 229920000573 polyethylene Polymers 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 abstract description 3
- 230000002601 intratumoral effect Effects 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000001556 precipitation Methods 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000013077 target material Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 238000011001 backwashing Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- YHTTWXCDIRTOQX-FQJIPJFPSA-N (6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O)C(O)=O YHTTWXCDIRTOQX-FQJIPJFPSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 229960005540 iRGD Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a targeting material with a tumor penetrating property. The material is characterized in that the material is a linear block copolymer formed by covalent linkage of three parts such as a targeting polypeptide with a tumor penetrating property, polyethylene glycol and phospholipid, wherein a molar ratio of the targeting polypeptide to the polyethylene glycol to the phospholipid is 1:1:1. The invention further provides a preparation method and applications of the targeting material. The targeting material can be used for preparing tumor targeting liposomes or micelle drug delivery systems so as to provide a tumor penetrating property and increase intratumoral delivery efficiency of the drug delivery system.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, relate to a kind of cancer target material, is that a kind of tumor penetrates peptide modified targeting material and preparation method and application specifically.
Background technology
Tumor is the principal disease that threatens human health and life, and its sickness rate is tangible ascendant trend in recent years.Be the tumor resection primary tumor to the conventional treatments of tumor clinically at present and carry out carrying out systemic chemotherapy or radiotherapy after the lymph cleaning.But surgical operation can not thoroughly be removed tumor cell and neoplasm metastasis lymph node, thereby causes tumor recurrence; After the quiet notes administration of chemotherapeutics, to the tumor tissues non-selectivity, has serious general toxic and side effects; Radiotherapy tends to cause the serious local skin reaction of patient, hemogram variation, local mucous membrane reaction etc.Express on tumor cell or the tumor vascular endothelial cell a series of specific receptors are arranged, the cancer target material that utilizes its ligand modified biocompatible materials and prepare is owing to it can be positioned to the extensive concern that tumor tissues is subjected to researcher by the active targeting in vivo.But because the cancer target performance is poor, drug effect improves problems such as not obvious, present most cancer target materials do not enter clinical practice yet.Therefore, research and development high-performance cancer target material, improve extremely urgent to Targeting Performance and the therapeutic effect of tumor.
The RPAKPAR polypeptide is straight chain seven peptides that obtain by the display technique of bacteriophage screening, and it belongs to a kind of " CendR polypeptide ", namely has R/K-X-X-R/K structure (wherein X represents any one aminoacid) at the C end.This class polypeptide belongs to " tumor penetrating peptide ", and many existing cancer target polypeptide all meet this structure, as LyP-1, F3, iRGD etc.Studies show that RPAKPAR is gliomatous ligands specific, show tumor cell and tumor vascular dual affinity.Can make its target tumor blood vessel wall to tumor vascular affinity, and can making it penetrate the tumor vessel wall, the tumor penetrance penetrates into tumor tissues inside, affinity to tumor cell can make it be combined with tumor cell specific, therefore as targeted molecular, this class polypeptide is compared with general tumor cell targeted molecular has more obvious advantage.Prove that at present the RPAKPAR polypeptide has the mediation phage and penetrates the ability that tumor vessel enters tumor tissues inside, but Shang Weijian utilizes the report of the peptide modified targeting material of RPAKPAR.
Summary of the invention
In order to overcome the deficiencies in the prior art, the invention provides a kind of have tumor penetration performance cancer target material and preparation method and application.
A kind of targeting material with tumor penetration performance, it is characterized in that, this material be by the target polypeptide with tumor penetration performance, Polyethylene Glycol and phospholipid three parts by the covalently bound linear block copolymers that forms, wherein the mol ratio of target polypeptide, Polyethylene Glycol and phospholipid is 1:1:1.
Described aminoacid sequence with target polypeptide of tumor penetration performance is RPAKPAR.
The weight average molecular weight of described Polyethylene Glycol is 2000 ~ 5000.
Described phospholipid is a kind of in DSPE (DSPE), two palmityl PHOSPHATIDYL ETHANOLAMINE (DPPE), DOPE (DOPE), hydrogenated soya phosphatide acyl ethanolamine (HSPE), hydrogenation egg phosphatide acyl ethanolamine, soybean phospholipid acyl ethanolamine, the egg phosphatide acyl ethanolamine.
The complex that described target polypeptide is formed by connecting by covalent bond form and Polyethylene Glycol-phospholipid.
Described target polypeptide provides a free sulfhydryl groups, and Polyethylene Glycol-phospholipid provides a dimaleoyl imino, and both specific reaction take place and connect into covalent complex.
A kind of method for preparing above-mentioned targeting material, it is characterized in that, the concrete steps of this method are: adopt the synthetic C of solid-phase polypeptide synthetic method to hold the target polypeptide (aminoacid sequence is CRPAKPAR) of external cysteine (Cys), it is dissolved in the phosphate buffer (PBS) of pH7.0, get maleimide-Polyethylene Glycol-phosphatide complexes (Mal-PEG-PE) and be dissolved in dimethyl formamide (DMF), both mix the back stirring reaction and react completely to Mal-PEG-PE, remove excessive polypeptide and DMF, lyophilization, obtain target polypeptide-Polyethylene Glycol-phosphatide complexes, namely have the targeting material of tumor penetration performance.
The described application of targeting material in pharmaceutical carriers such as preparation liposome, micelle with tumor penetration performance.
Above-mentioned targeting material can be used to prepare pharmaceutical carriers such as liposome with tumor penetration performance, micelle, be expelled in the lotus tumor mouse body after, penetrable tumor vessel penetrates into tumor tissues inside, realizes the efficient targeting drug delivery to tumor.The present invention adopts tumor penetrating peptide RPAKPAR decorated phospholipid to obtain having the targeting material RPAKPAR-PEG-PE of tumor penetration performance, can be used to prepare cancer target liposome or micelle.
The targeting material of the present invention's protection can be used for preparing cancer target liposome or micelle delivery system, gives its tumor penetration performance, improves the interior transmission efficiency of tumor of delivery system.
Description of drawings
The 1H-NMR collection of illustrative plates of accompanying drawing 1, RPAKPAR-PEG-DSPE.
A is the nuclear magnetic spectrum of Mal-PEG-DSPE among the figure, and B is RPAKPAR
-The nuclear magnetic spectrum of PEG-DSPE, as can be seen from Figure, A figure demonstrates the maleimide peak, and this peak disappears among the B figure, and all the other peaks remain unchanged substantially, show that the maleimide base group among the Mal-PEG-DSPE reacts with CRPAKPAR.
Accompanying drawing 2, the fluorescein-labelled liposome that utilizes RPAKPAR-PEG-DSPE to prepare are absorbed photo by tumor cell.
Utilize fluorescein-labelled liposome that RPAKPAR-PEG-DSPE prepares and common fluorescein-labelled liposome in 37 ℃ respectively with the fluorescence micrograph of U87 tumor cell effect after 2 hours, as seen from the figure, tumor cell to the intake of RPAKPAR modified liposome much larger than conventional liposome.
The specific embodiment
To help further to understand the present invention by following embodiment, but not limit content of the present invention.
Embodiment 1: synthetic, the purification of targeting material RPARPAR-PEG-DSPE and sign.
Be tertbutyloxycarbonyl-arginine (p-toluenesulfonyl)-acetparaminosalol benzyl ester of 0.6mmol/g with substitution value) oc-Arg (Tos)-PAM resin N, dinethylformamide DMF swelling is drained, and reuse trifluoroacetic acid TFA sloughs the Boc protecting group, take out TFA, wash with DMF; With BTA-N, N, N', DMF solution and the N of N'-tetramethylurea hexafluorophosphate HBTU, N-diisopropylethylamine DIEA activates tertbutyloxycarbonyl-alanine Boc-Ala, gets the Boc-Ala activating solution; With the Boc-Ala activating solution of the resin adding gained after the DMF washing, 25 ℃ of joltings were reacted 25 minutes, took out dereaction liquid, and used the DMF washing resin; Repeat above steps, connect all the other aminoacid in turn by the CRPAKPAR sequence; Reaction finishes back washing resin, TFA deprotection base, behind the vacuum drying, puts into polypeptide cutting pipe, adds an amount of P-cresol, feeds HF then, ice bath stirring reaction 1 hour; Reaction finishes the back decompression and takes out HF in the pipe, and residual liquid is with an amount of ice ether sedimentation, filter precipitation and with icing the ether washing precipitation; Precipitation with the TFA dissolving, filters to get filtrate again; Filtrate is precipitated in the ice ether again, filters, and filtering residue redissolves with water, and lyophilizing gets the pure product of CRPAKPAR; Get then in the 2ml PBS solution that the pure product 50mg of CRPAKPAR is dissolved in pH7.0, getting maleimide-Polyethylene Glycol-phosphatide complexes Mal-PEG-DSPE(molar equivalent is 0.8 times of CRPAKPAR) be dissolved in DMF, stirring reaction reacts completely to Mal-PEG-DSPE, remove excessive CRPARPAR and DMF, lyophilization, obtain RPARPAR-PEG-DSPE, NMR characterizes its structure, the result shows, the Mal-PEG-DSPE collection of illustrative plates shows the characteristic peak of Mal at the 6.67ppm place, and this peak disappears on the RPARPAR-PEG-DSPE collection of illustrative plates, illustrates that RPARPAR-PEG-DSPE synthesizes successfully.
Embodiment 2: synthetic, the purification of targeting material RPARPAR-PEG-HSPE and sign.
Be tertbutyloxycarbonyl-arginine (p-toluenesulfonyl)-acetparaminosalol benzyl ester of 0.6mmol/g with substitution value) oc-Arg (Tos)-PAM resin N, dinethylformamide DMF swelling is drained, and reuse trifluoroacetic acid TFA sloughs the Boc protecting group, take out TFA, wash with DMF; With BTA-N, N, N', DMF solution and the N of N'-tetramethylurea hexafluorophosphate HBTU, N-diisopropylethylamine DIEA activates tertbutyloxycarbonyl-alanine Boc-Ala, gets the Boc-Ala activating solution; With the Boc-Ala activating solution of the resin adding gained after the DMF washing, 25 ℃ of joltings were reacted 25 minutes, took out dereaction liquid, and used the DMF washing resin; Repeat above steps, connect all the other aminoacid in turn by the CRPAKPAR sequence; Reaction finishes back washing resin, TFA deprotection base, behind the vacuum drying, puts into polypeptide cutting pipe, adds an amount of P-cresol, feeds HF then, ice bath stirring reaction 1 hour; Reaction finishes the back decompression and takes out HF in the pipe, and residual liquid is with an amount of ice ether sedimentation, filter precipitation and with icing the ether washing precipitation; Precipitation with the TFA dissolving, filters to get filtrate again; Filtrate is precipitated in the ice ether again, filters, and filtering residue redissolves with water, and lyophilizing gets the pure product of CRPAKPAR; Get then in the 2ml PBS solution that the pure product 50mg of CRPAKPAR is dissolved in pH7.0, getting maleimide-Polyethylene Glycol-phosphatide complexes Mal-PEG-HSPE(molar equivalent is 0.8 times of CRPAKPAR) be dissolved in DMF, stirring reaction reacts completely to Mal-PEG-HSPE, remove excessive CRPARPAR and DMF, lyophilization, obtain RPARPAR-PEG-HSPE, NMR characterizes its structure, the result shows, the Mal-PEG-HSPE collection of illustrative plates shows the characteristic peak of Mal at the 6.67ppm place, and this peak disappears on the RPARPAR-PEG-HSPE collection of illustrative plates, illustrates that RPARPAR-PEG-HSPE synthesizes successfully.
Embodiment 3: synthetic, the purification of targeting material RPARPAR-PEG-DOPE and sign.
Be tertbutyloxycarbonyl-arginine (p-toluenesulfonyl)-acetparaminosalol benzyl ester of 0.6mmol/g with substitution value) oc-Arg (Tos)-PAM resin N, dinethylformamide DMF swelling is drained, and reuse trifluoroacetic acid TFA sloughs the Boc protecting group, take out TFA, wash with DMF; With BTA-N, N, N', DMF solution and the N of N'-tetramethylurea hexafluorophosphate HBTU, N-diisopropylethylamine DIEA activates tertbutyloxycarbonyl-alanine Boc-Ala, gets the Boc-Ala activating solution; With the Boc-Ala activating solution of the resin adding gained after the DMF washing, 25 ℃ of joltings were reacted 25 minutes, took out dereaction liquid, and used the DMF washing resin; Repeat above steps, connect all the other aminoacid in turn by the CRPAKPAR sequence; Reaction finishes back washing resin, TFA deprotection base, behind the vacuum drying, puts into polypeptide cutting pipe, adds an amount of P-cresol, feeds HF then, ice bath stirring reaction 1 hour; Reaction finishes the back decompression and takes out HF in the pipe, and residual liquid is with an amount of ice ether sedimentation, filter precipitation and with icing the ether washing precipitation; Precipitation with the TFA dissolving, filters to get filtrate again; Filtrate is precipitated in the ice ether again, filters, and filtering residue redissolves with water, and lyophilizing gets the pure product of CRPAKPAR; Get then in the 2ml PBS solution that the pure product 50mg of CRPAKPAR is dissolved in pH7.0, getting maleimide-Polyethylene Glycol-phosphatide complexes Mal-PEG-DOPE(molar equivalent is 0.8 times of CRPAKPAR) be dissolved in DMF, stirring reaction reacts completely to Mal-PEG-DOPE, remove excessive CRPARPAR and DMF, lyophilization, obtain RPARPAR-PEG-DOPE, NMR characterizes its structure, the result shows, the Mal-PEG-DOPE collection of illustrative plates shows the characteristic peak of Mal at the 6.67ppm place, and this peak disappears on the RPARPAR-PEG-DOPE collection of illustrative plates, illustrates that RPARPAR-PEG-DOPE synthesizes successfully.
Embodiment 4: synthetic, the purification of targeting material RPARPAR-PEG-DPPE and sign.
Be tertbutyloxycarbonyl-arginine (p-toluenesulfonyl)-acetparaminosalol benzyl ester of 0.6mmol/g with substitution value) oc-Arg (Tos)-PAM resin N, dinethylformamide DMF swelling is drained, and reuse trifluoroacetic acid TFA sloughs the Boc protecting group, take out TFA, wash with DMF; With BTA-N, N, N', DMF solution and the N of N'-tetramethylurea hexafluorophosphate HBTU, N-diisopropylethylamine DIEA activates tertbutyloxycarbonyl-alanine Boc-Ala, gets the Boc-Ala activating solution; With the Boc-Ala activating solution of the resin adding gained after the DMF washing, 25 ℃ of joltings were reacted 25 minutes, took out dereaction liquid, and used the DMF washing resin; Repeat above steps, connect all the other aminoacid in turn by the CRPAKPAR sequence; Reaction finishes back washing resin, TFA deprotection base, behind the vacuum drying, puts into polypeptide cutting pipe, adds an amount of P-cresol, feeds HF then, ice bath stirring reaction 1 hour; Reaction finishes the back decompression and takes out HF in the pipe, and residual liquid is with an amount of ice ether sedimentation, filter precipitation and with icing the ether washing precipitation; Precipitation with the TFA dissolving, filters to get filtrate again; Filtrate is precipitated in the ice ether again, filters, and filtering residue redissolves with water, and lyophilizing gets the pure product of CRPAKPAR; Get then in the 2ml PBS solution that the pure product 50mg of CRPAKPAR is dissolved in pH7.0, getting maleimide-Polyethylene Glycol-phosphatide complexes Mal-PEG-DPPE(molar equivalent is 0.8 times of CRPAKPAR) be dissolved in DMF, stirring reaction reacts completely to Mal-PEG-DPPE, remove excessive CRPARPAR and DMF, lyophilization, obtain RPARPAR-PEG-DPPE, NMR characterizes its structure, the result shows, the Mal-PEG-DPPE collection of illustrative plates shows the characteristic peak of Mal at the 6.67ppm place, and this peak disappears on the RPARPAR-PEG-DPPE collection of illustrative plates, illustrates that RPARPAR-PEG-DPPE synthesizes successfully.
Embodiment 5: the preparation of liposome and tumor cell in vitro picked-up experiment thereof.
Liposome membrane material prescription consists of the HSPC(hydrogenated soya phosphatide)/the Chol(cholesterol)/mPEG-DSPE(Polyethylene Glycol-DSPE complex) (55:45:2, mol/mol), the PEG liposome membrane material prescription that RPARPAR modifies for HSPC/Chol/mPEG-DSPE/RPARPAR-PEG-DSPE (55:45:2:0.5, mol/mol).Take by weighing above-mentioned membrane material and be dissolved in chloroform, the decompression rotary evaporation is removed organic solvent, gets even lipid film, vacuum drying 24 hours.Add FAM aqueous solution aquation, 60 ℃ of water-baths were shaken 2 hours, got liposome turbid liquor.In 60 ℃ of water-baths, use miniature extruder successively liposome to be pushed 400,200,100 and the 50nm nucleopore membranes, its particle diameter is reduced.Be that eluent is crossed sephadex G-50 chromatographic column and separated and to remove non-encapsulated FAM then with the normal saline, get liposome.Two kinds of liposomees and tumor cell are hatched 4h altogether, inhale and abandon supernatant, and PBS cleans, laser confocal microscope observation of cell liposome picked-up situation.The result shows that conventional liposome is ingested hardly, and the liposome that RPARPAR modifies illustrates that then by huge uptake the targeting material RPARPAR-PEG-DSPE that RPARPAR modifies has given the external targeting of liposome to tumor cell.
Claims (8)
1. targeting material with tumor penetration performance, it is characterized in that, this material be by the target polypeptide with tumor penetration performance, Polyethylene Glycol and phospholipid three parts by the covalently bound linear block copolymers that forms, wherein the mol ratio of target polypeptide, Polyethylene Glycol and phospholipid is 1:1:1.
2. according to the described targeting material with tumor penetration performance of claim 1, it is characterized in that described aminoacid sequence with target polypeptide of tumor penetration performance is RPAKPAR.
3. according to the described targeting material with tumor penetration performance of claim 1, it is characterized in that the weight average molecular weight of described Polyethylene Glycol is 2000 ~ 5000.
4. according to the described targeting material with tumor penetration performance of claim 1, it is characterized in that described phospholipid is a kind of in DSPE (DSPE), two palmityl PHOSPHATIDYL ETHANOLAMINE (DPPE), DOPE (DOPE), hydrogenated soya phosphatide acyl ethanolamine (HSPE), hydrogenation egg phosphatide acyl ethanolamine, soybean phospholipid acyl ethanolamine, the egg phosphatide acyl ethanolamine.
5. according to the described targeting material with tumor penetration performance of claim 1, it is characterized in that the complex that described target polypeptide is formed by connecting by covalent bond form and Polyethylene Glycol-phospholipid.
6. according to the described targeting material with tumor penetration performance of claim 1, it is characterized in that, described target polypeptide provides a free sulfhydryl groups, and Polyethylene Glycol-phospholipid provides a dimaleoyl imino, and both specific reaction take place and connect into covalent complex.
7. one kind prepares according to claim 1,2,3,4,5, the method of 6 each described targeting materials, it is characterized in that, the concrete steps of this method are: adopt the synthetic C of solid-phase polypeptide synthetic method to hold the target polypeptide (aminoacid sequence is CRPAKPAR) of external cysteine (Cys), it is dissolved in the phosphate buffer (PBS) of pH7.0, get maleimide-Polyethylene Glycol-phosphatide complexes (Mal-PEG-PE) and be dissolved in dimethyl formamide (DMF), both mix the back stirring reaction and react completely to Mal-PEG-PE, remove excessive polypeptide and DMF, lyophilization, obtain target polypeptide-Polyethylene Glycol-phosphatide complexes, namely have the targeting material of tumor penetration performance.
8. according to the claim 1-6 described application of targeting material in pharmaceutical carriers such as preparation liposome, micelle with tumor penetration performance arbitrarily.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310166384XA CN103263674A (en) | 2013-05-08 | 2013-05-08 | Tumor targeting material with tumor penetrating property, preparation method and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310166384XA CN103263674A (en) | 2013-05-08 | 2013-05-08 | Tumor targeting material with tumor penetrating property, preparation method and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103263674A true CN103263674A (en) | 2013-08-28 |
Family
ID=49007364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310166384XA Pending CN103263674A (en) | 2013-05-08 | 2013-05-08 | Tumor targeting material with tumor penetrating property, preparation method and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103263674A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626993A (en) * | 2013-11-05 | 2014-03-12 | 南京理工大学 | Polyethylene glycol monomethyl ether soybean phosphatidyl ethanolamine derivative and preparation thereof |
| CN103656652A (en) * | 2013-12-10 | 2014-03-26 | 深圳先进技术研究院 | Dual-sensing response type polymer nano-micelle as well as preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102516391A (en) * | 2011-12-23 | 2012-06-27 | 上海纳米技术及应用国家工程研究中心有限公司 | Neuropilin-1 ligand polypeptide-polyethylene glycol-phospholipid composite, its active targeting liposome vector system and preparation method thereof |
-
2013
- 2013-05-08 CN CN201310166384XA patent/CN103263674A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102516391A (en) * | 2011-12-23 | 2012-06-27 | 上海纳米技术及应用国家工程研究中心有限公司 | Neuropilin-1 ligand polypeptide-polyethylene glycol-phospholipid composite, its active targeting liposome vector system and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626993A (en) * | 2013-11-05 | 2014-03-12 | 南京理工大学 | Polyethylene glycol monomethyl ether soybean phosphatidyl ethanolamine derivative and preparation thereof |
| CN103626993B (en) * | 2013-11-05 | 2016-01-20 | 南京理工大学 | Polyethylene glycol monomethyl ether soybean phosphatidyl ethanolamine derivative and preparation thereof |
| CN103656652A (en) * | 2013-12-10 | 2014-03-26 | 深圳先进技术研究院 | Dual-sensing response type polymer nano-micelle as well as preparation method and application thereof |
| CN103656652B (en) * | 2013-12-10 | 2015-09-09 | 深圳先进技术研究院 | A kind of double sensitive responsive polymer nanomicelle and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shi et al. | A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma | |
| Zhang et al. | Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment | |
| CN102516361B (en) | NRP-1 ligand polypeptide-polyethylene glycol-phosphatide compound, active targeting liposome drug delivery system mediated thereby and preparation method thereof | |
| CN101791411B (en) | Preparation and application of amphiphilic polysaccharide conjugate and pharmaceutical composition thereof | |
| CN110237035B (en) | An active targeting amphiphilic polypeptide nano drug carrier and its preparation and application | |
| CN102091036A (en) | Compound liposome containing anti-tumor drugs and preparation method and application thereof | |
| CN103976954A (en) | Drug-loaded liposome co-modified by folic acid and TAT peptide and preparation method thereof | |
| CN103656650B (en) | A pH-sensitive brain tumor dual-stage targeted nano drug delivery system and its preparation method and application | |
| Qiu et al. | αvβ3 integrin receptor specific peptide modified, salvianolic acid B and panax notoginsenoside loaded nanomedicine for the combination therapy of acute myocardial ischemia | |
| CN103720655B (en) | Target liposomes of a kind of D type polypeptide mediation and its preparation method and application | |
| CN106214640A (en) | A kind of cancer target passs liposome delivery systems and the preparation method and application of medicine | |
| CN113004536A (en) | A metal-amino acid/peptide coordination polymer and its application | |
| CN103371975A (en) | Targeted long-circulation liposome preparation and preparation method thereof | |
| CN102516391A (en) | Neuropilin-1 ligand polypeptide-polyethylene glycol-phospholipid composite, its active targeting liposome vector system and preparation method thereof | |
| CN104490786B (en) | Preparation method and application of targeted multi-function double drug-loading liposome | |
| CN103316354A (en) | Tumor targeting polypeptide-polyethylene glycol-polylactic acid compound, preparation method thereof and applications thereof | |
| CN111481507A (en) | A kind of enzymatic cationized liposome and its application | |
| CN104586765B (en) | A kind of brain tumor targeting drug delivery system and preparation method thereof | |
| CN111450252B (en) | Medicine for targeted blocking of tumor blood vessels and preparation method and application thereof | |
| CN107854431B (en) | A kind of hyaluronic acid nanomicelle targeting to hepatic stellate cell and its preparation method and application | |
| KR101429668B1 (en) | Nanoparticles comprising amphiphilic low molecular weight hyaluronic acid complex and a process for the preparation thereof | |
| CN103536930B (en) | Polylactic acid-polyethylene glycol-tumor penetrating peptide compound, preparation and application thereof | |
| CN104341488A (en) | c(LyP-1) polypeptide and nano-delivery system constructed thereby and application of nano-delivery system | |
| CN104045823B (en) | A kind of glycyrrhetinic acid derivative and its preparation method and application | |
| CN103263674A (en) | Tumor targeting material with tumor penetrating property, preparation method and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130828 |